Sep 12, 2025 7:00 AM Eastern Daylight Time United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress Share Results of the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented in an oral presentation SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent rese ...